Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
NEW YORK, Sept. 05, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired American Depositary Shares of Teva Pharmaceutical Industries Ltd. ("Teva") (NYSE:TEVA) between November 15, 2016 and August 2, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania. To get more information go to:
http://www.zlk.com/pslra-sbm/teva-pharmaceutical-industries-ltd?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose adverse information concerning the Company’s business and outlook. In particular, it is alleged that Teva failed to disclose and/or omitted the true negative impact of the acquisition and integration of Actavis Generics on the Company’s financial results and business prospects.
If you suffered a loss in Teva you have until October 23, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
